KUALA LUMPUR, Oct 7 — PVH Europe, the global headquarters of Tommy Hilfiger and the European offices of Calvin Klein has installed the world’s most powerful currently operational solar roof at its Warehouse and Logistics Center in Venlo, the Netherlands.
PVH defines the ‘world’s most powerful solar roof’ as the most powerful solar roof that is currently operational and installed on one singular structure.
Generated by over 48,000 solar panels, the solar roof covers the Center’s electricity footprint, as well as indirectly providing 100 per cent of all energy for PVH Europe’s warehouses, offices and stores in the Netherlands via the Dutch public power network.
According to a statement, PVH Europe’s energy partner, Eneco, has certified that all energy needed to power these buildings is generated by the new rooftop installation.
This milestone marks another step in PVH’s journey to procure 100 per cent of its electricity from renewable sources for its offices, warehouses and stores, and to drive a 30 per cent reduction in supply chain carbon emissions by 2030.
The Venlo warehouse is PVH Europe’s main distribution centre covering 110,000m² and has been awarded a ‘Very Good’ rating of Building Research Establishment Environmental Assessment Method.
Currently, up to 600,000 pieces of TOMMY HILFIGER and CALVIN KLEIN product are distributed daily from the PVH Europe Warehouse and Logistics Center in Venlo to points of sale, including owned and operated stores in Europe, the Middle East and Africa and direct to customers.
With the new contract, PRA will assist Biomedical Advanced Research and Development Authority (BARDA) in the development of medical countermeasures for public health
RALEIGH, N.C., Oct 7 (Bernama-GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today it has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to be a member of its updated Clinical Studies Network (CSN). Under a Clinical Trial Planning and Execution (CTPE) contract award, PRA will serve as a valued partner that provides clinical research services to develop medical countermeasures (MCMs) that protect health and save lives in public health emergencies.
“This program represents important research that is necessary to protect and facilitate public health,” said Michael Massaro, Senior Vice President, Project Delivery and Biometrics, PRA Health Sciences. “We are proud to support BARDA’s Clinical Studies Network where we can offer our clinical research experience, expertise, and capabilities and be a healthcare intelligence partner for this unique and urgent need.”
As part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), BARDA aids in securing the nation from chemical, biological, radiological, and nuclear threats, as well as pandemic influenza and emerging infectious diseases. BARDA supports the advanced research, development and manufacturing of MCMs, such as vaccines, drugs, and diagnostics. BARDA will leverage the CSN to advance the development of MCMs by conducting rigorous Phase I-IV clinical trials that assess the safety and efficacy of drugs, devices, and biological products.
BARDA recently reconfigured the CSN contract to include the Clinical Trial Planning and Execution contract as a multi-award Indefinite Delivery/Indefinite Quantity contract over a five-year period. During the term of their contract, PRA and other CSN CTPE members can submit additional proposals for new work within the project’s scope. This project has been funded in whole or in part with federal funds from ASPR and BARDA, under Contract No. 75A50120D00019.
About PRA Health Sciences
PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, Africa, Australia and the Middle East and more than 17,500 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.
KUALA LUMPUR, Oct 5 — The Korean historic site, Jeolla Gamyoung, which has been restored to its original grandeur, will open on Oct 7.
Entitled ‘Jeolla Gamyoung: A Radiant Flower, A Thousand Years of Fruit’, the ceremony will be attended by a small number of participants to prevent the spread of Covid-19 and live-streamed on YouTube.
According to a statement by Jeonju City, ‘Gamyoung’ referred to a provincial government complex in the Joseon Dynasty while Jeolla is the southwestern province of the country.
The celebration will begin with ‘Seungjeonmu’ (Victory Dance), followed by the unveiling of the signboard of ‘Seonhwadang’, the main building on Jeolla Gamyoung.
Jeonju citizens and residents in North Jeolla Province will deliver a book of their wishes for the future of Jeolla Gamyoung to Jeonju mayor and Jeollabuk-do governor.
A ceremony for the transfer of duties of Jeolla governor will be enacted based on entries written by Jeolla Gov. Lee Seok-pyo in his ‘Honam Diary.’ Honam is another name for Jeolla.
Discussion to restore the ancient government complex began in 2005. The ground was broken for the project in November 2017 after the old Jeollabuk-do government building was demolished.
The first stage, which was completed on Aug 27, focused to find records on the original form of Jeolla Gamyoung. Seven major buildings were restored during this phase.
Jeonju will kick off the second stage of the project shortly after deciding on the plan to develop the west zone of Jeolla Gamyoung. Until then, the zone will remain open to the general public.
PTR Robots was developed and tested in close collaboration with Zealand University Hospital, and Vonsildhave Nursing Home, operated by the nursing group Attendo. “The testing of PTR Robots really impressed us. We can see interesting perspectives in the way we can assist residents and patients with care and rehabilitation, but there are also interesting perspectives in terms of improving the work environment,” says Søren Andersen, Managing Director, Attendo. (Photo: Business Wire)
Patient transfer and rehabilitation robot is mobile and intelligent
ODENSE, Denmark, Oct 2 (Bernama-BUSINESS WIRE) — PTR Robots, a Danish service-robot company, announced the world premiere of its robot that can mobilize and transfer patients. Jointly developed with healthcare professionals, the PTR Robot is the first mobile, intelligent robot solution that can flexibly move around in the healthcare and nursing sectors. While it helps individuals with impaired functions to be transferred and rehabilitated, it also relieves the strain on staff, redirecting them from labor-intensive tasks. A PTR Robot also reduces the risk of infection, because only one caregiver needs to be present to perform a patient transfer.
One out of every four bedridden patients in a typical hospital is not self-reliant and needs assistance, both to be transferred and rehabilitated. This need is even more pronounced at nursing homes. According to the WHO, lifting injuries account for one-third of all occupational injuries among nurses.
“Many nursing homes, hospitals and institutions are keenly interested in our patient transfer and rehabilitation robot. If an elderly person breaks his or her hip, the robot can help him/her stand up right after the operation. The robot also accompanies the patient when taking the first steps after surgery,” says Lone Jager Lindquist CEO, PTR Robots.
KUALA LUMPUR, Oct 1 — Biotalys NV, a transformative food and crop protection company has been awarded a €1.1 million research grant from Flanders Innovation & Entrepreneurship (VLAIO). (€1 = RM4.856)
According to a statement, the grant will run over three years and support the development of the Company’s novel protein-based bio-bactericides for the management of bacterial plant diseases.
“We are very pleased with the financial support and recognition from VLAIO and their commitment to continue to stimulate entrepreneurship and innovation in Belgium,” said Biotalys CSO, Hilde Revets.
“The funding will allow us to accelerate our research and development activities of our protein-based biocontrol solutions with completely new mechanisms-of-action for the management of bacterial plant diseases, including cankers, blight and spots,” added Revets.
“Bacterial diseases cause major damage to food and crops around the world and there is an urgent need for novel and safe solutions with consistent high efficacy to protect crops and reduce food waste,” said Biotalys CFO, Wim Ottevaere.
“We strongly believe that our bio-bactericide programme has the potential to address these needs and we look forward to progressing this innovative biocontrol further in development.”
wonderland 